then why is continuing to drop off the pre-market highs? It just keeps getting faded. These were good
numbers....does anyone think shorts are manipulating to cover lower, or is there another issue?
YY: Hard To Argue Against A Solid Q3 Beat
By Shuli Ren
Chinese Internet names are not cheap. When the companies do their earnings, investors scrutinize everything, from revenue and eyeball growth to margins and business outlook.
It would be hard to pick on YY (YY) this time. China’s Google Hangout has beaten the consensus by a solid margin.
In the third-quarter, revenue at YY grew 105% from a year ago to $163 million, 7.4% higher than the consensus. Its operating margin improved as well, to 34.5% from 32.7% in the second-quarter, “mainly driven by the company’s operating leverage,” noted Barclays. In plain words, the more revenue YY pulls in, the less average fixed cost it incurs.
For the fourth-quarter, YY expects revenue to grow 76-80% year-on-year to $176-179 million, with the midpoint of $177.5 million beating the consensus of $173.5 million.
Shares of YY have fallen over 10% in the last three months and have gotten “cheap.” It trades at “only” 21
times forward earnings, below its historical average of 24 times. Analysts polled by Factset expect 43% earnings growth next year and in 2016.
Somewhat muted in AH, but I think it head much higher tomorrow. This story continues to get better. Jack Ma should add YY to his empire.
There has to be something out there that would adversely effect corporate earnings long term,
a catalyst such as a serious geopolitical event. Short of that, the irrational exuberance will unfortunately probably continue; the greed out there is beyond belief.
When the hell is this market going to fall? If I read one more article about "seasonality", I'm going to scream. These talking heads try anything they can to manipulate the markets. A parabolic move off a low point is
unhealthy, and unsustainable.
BABA, BITA, ATHM, YY, and BIDU.....
Muddy has a habit of researching Chinese companies and calling out those he thinks their price advance is unwarranted because of possible fraud. Alibaba is a Chinese company. All men are mortal. Socrates is a man, therefore Socrates is mortal. I'm not suggesting anything, I'm just saying.....
BABA does $10B in revenue, and has a market cap of $282B. That's insane at any growth level. Apple on the other hand does $183B in revenue, and their market cap is $638B. Apple of course is a much more
You have that, plus I think traders are rethinking China. I mean, the Chinese are famous for changing the rules, and making it more difficult for companies, so there could be some restrictions set at any time. Simply put, at this valuation, the risks outweigh the reward.
It just can't seem to hold the gain, at least so far. Trading over $2 off the highs with blowout earnings is an
issue for me, but maybe that will change and it will close over that high, we'll see.
The market falls and starts a downtrend when you least expect it. In my heart of hearts (whatever that means) I believe today was the last day of the rally for awhile (awhile defined as at least 4 weeks.) Longs, although it's not perfect, watch out for that doji print on the S&P daily chart today.
I've been a huge bull on INSY like you for sometime, but I have to say, it's just not trading right. I mean, the chart looks like it's in the process of breaking down. Regrettably, retail investors like us are always the last to know if there's any bad news. Technically, the stock has to hold the $34-$35 range next week, if that fails, it could fall all the way to near $25 in time.
I'll weigh in without seeing the report. Any good news on their flagship drug to reported later this month is
already priced into the stock, at least that's what Goldman is saying. How much more upside can you expect from a biotech company in Phase I trials? The other issue is biotechs are all getting hammered today
because of the accounting mess over at SLXP, as well as ICPT crashing and burning.